Xenikos (Netherlands)
In June 2022, Xenikos commenced a global Phase 3 clinical study evaluating T-Guard® in patients with grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (NCT04934670). In early 2023, following a review of the ongoing study data the Data Safety and Monitoring Board (DSMB) recommended that the study should be discontinued. Although we feel that the DSMB’s conclusion may be premature, patient safety is our highest priority;
Basic Information
- Category: business
- Website: http://www.xenikos.com/
Documented Facts
- Email: info@xenikos.com (No linked source recorded for this statement.)
Evidence and Sources
- Xenikos (Netherlands) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Xenikos (Netherlands).
- Canonical profile: https://brandsource.ai/brands/xenikos-netherlands
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/xenikos-netherlands/json-ld
- Citation profile API: https://brandsource.ai/api/brands/xenikos-netherlands/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
In June 2022, Xenikos commenced a global Phase 3 clinical study evaluating T-Guard® in patients with grade III/IV steroid-refractory acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic stem cell transplant (NCT04934670). In early 2023, following a review of the ongoing study data the Data Safety and Monitoring Board (DSMB) recommended that the study should be discontinued. Although we feel that the DSMB’s conclusion may be premature, patient safety is our highest priority;
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.